Printer Friendly

Germany,Switzerland : Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network.

Investment to help meet rising demand for licensed biologics and expected pipeline growth

Roche today announced plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. The investment will be spread across sites in Penzberg (Germany), Basel (Switzerland), as well as Vacaville and Oceanside (USA). Approximately 500 new jobs are expected to be created in conjunction with the facility expansions.

"Biologic medicines have become an essential part of modern medicine and play an important role in improving the lives of patients. As the world s largest supplier of biologics, Roche is committed to making the necessary investments to ensure ongoing supply of these medicines at the highest quality standards said Daniel O Day, Chief Operating Officer of Roche s Pharmaceuticals Division. Increasing our manufacturing capacity also highlights the confidence we have in the research and development of a range of new biologic medicines that will help serve unmet medical needs.

The investment will support increasing demand for licensed biologic medicines, such as RoACTEMRA (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), alongside providing a strong foundation for the delivery of 39 investigational biologic medicines in the Roche pipeline.

Biologic manufacturing capacity will be increased at sites in Vacaville and Oceanside in California, U.S with a planned investment of approximately 260 million Swiss francs creating around 250 new jobs. In Penzberg, Germany, Roche will invest approximately 350 million Swiss francs toward increased manufacturing capacity and equipment refurbishment, creating around 200 positions.

In addition, construction of an antibody-drug conjugate (ADC) production facility will begin in Basel, Switzerland through an investment of over 190 million Swiss francs, which is expected to create 50 jobs. This investment will provide additional capacity and flexibility to support Roche s first approved ADC, Kadcyla, and a further eight ADCs in clinical development.

About biologics and their manufacturing

Biologic medicines are large molecules that are created by biological processes, rather than being chemically synthesised and are typically administered via injection or intravenously. Roche is a world leader in biologic medicine manufacturing, with long-standing expertise in biotech manufacturing and has the largest biotech production capacity of any company worldwide.

The biologics unit at Roche consists of several manufacturing sites in North America, Europe and Asia, which work as a closely aligned network focused on all aspects of biologic medicine manufacturing and supply.

2013 Al Bawaba (

Provided by an company
COPYRIGHT 2013 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:4EUGE
Date:Oct 15, 2013
Previous Article:Germany : AASU and MARTIN LUTHER UNIVERSITY ink MoU to strengthen their relationship.
Next Article:Germany : Boehringer Ingelheim submits nintedanib, a novel oncology compound, for European approval.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters